Core Insights - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The company’s lead candidate, ONP-002, is in Phase IIa clinical development for treating concussion and mild traumatic brain injury (mTBI), which affects approximately 69 million people globally each year without any approved pharmacological treatment [3] - The company received an unqualified audit opinion from its independent accounting firm regarding its financial statements, which included a paragraph about its ability to continue as a going concern [1] Financial Information - The audited consolidated financial statements for the fiscal year ended December 31, 2025, were filed on March 16, 2026, with the Securities and Exchange Commission [1][2] - The announcement regarding the audit opinion is made in compliance with NYSE American LLC Company Guide Section 610(b) [1] Company Overview - Oragenics is exploring the expansion of its central nervous system (CNS) pipeline strategy through both internal development and strategic business development [3] - The company’s intranasal delivery platform aims to provide rapid, non-invasive delivery of therapeutics directly to the brain, bypassing the blood-brain barrier [3]

Core Insights - Oragenics, Inc. has reported significant operational and clinical advancements in 2025, marking a year of strategic transformation and a clear path forward for the company [3][6]. Financial Performance - The company completed a successful capital raise of $16.5 million, strengthening its balance sheet and funding the advancement of its lead candidate, ONP-002, through Phase IIa clinical trials in Australia [4]. - Operating expenses were reduced by 11% year over year, primarily driven by reductions in R&D expenses and overhead salaries [4]. - The net cash used in operations was approximately $9 million, while net cash from financing was approximately $16.8 million [4]. Operational Milestones - Oragenics regained full compliance with NYSE American listing requirements, reflecting improved governance and shareholder alignment [4]. - The company engaged a qualified clinical research organization to lead Phase IIa trial operations across three sites in Australia [4]. - Drug manufacturing was moved from China to the United States, contracting Sterling Pharma Solutions for FDA cGMP manufacturing in Cary, North Carolina [4]. - A strategic partnership was established with Receptor.AI to leverage artificial intelligence in CNS drug discovery, expanding the company's pipeline development capabilities [4]. Clinical Development - The company received Human Research Ethics Committee (HREC) approval in Australia, the final regulatory clearance required to begin patient dosing in the Phase IIa trial of ONP-002 [4]. - The first site initiation visit at the initial Australian clinical trial site was completed, with two additional sites advancing through final Research Governance Office reviews [4]. - All three sites in Australia are expected to complete the RGO review soon, allowing for patient enrollment and dosing to commence [4]. Strategic Focus for 2026 - The CEO emphasized that 2026 will focus on executing the company's strategic plans rather than resetting, with an active exploration of expanding the CNS platform [6]. - The company is pursuing discussions with potential partners regarding the acquisition of additional CNS assets that are synergistic with ONP-002 and its intranasal delivery platform [4].

Financial Performance - The company reported net losses of $9.8 million and $10.6 million for the years ended December 31, 2025, and 2024, respectively, with an accumulated deficit of $226.6 million as of December 31, 2025[344]. - The company has incurred substantial losses and negative cash flow since inception, raising doubts about its ability to continue as a going concern[346]. - The company had an accumulated deficit of $226.6 million as of December 31, 2025, and has not yet achieved profitability[396]. - The company anticipates being able to fund its operating expenses through the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern[397]. Research and Development - The expected timeline for the ONP-002 clinical trials includes starting Phase 2a in Q1 2026 and Phase 3 in Q1 2028[338]. - The company plans to increase research and development expenses as it advances the ONP-002 program while pausing other product candidates pending additional financing[363]. - The company anticipates significant expenditures related to research and development activities, including clinical trials and regulatory submissions[345]. - Research and development expenses decreased to $2.4 million in 2025 from $4.1 million in 2024, a reduction of $1.7 million or 41.8%[388]. Cash and Financing Activities - As of December 31, 2025, the company had $8.4 million in cash and cash equivalents, expected to fund operations through Q3 2026[352]. - The company raised approximately $15 million from a public offering of 660,000 shares of Series H Convertible Preferred Stock on July 2, 2025[342]. - Net cash provided by financing activities was $16.8 million in 2025, up from $6 million in 2024[402]. - Financing activities in 2025 included $15.0 million in net proceeds from the issuance of Series H Preferred Stock and warrants, $2.6 million from common stock issuance, and $2.5 million from short-term borrowings, offset by $3.3 million in repayments of short-term notes payable[403]. - In 2024, financing activities consisted of $6.7 million in net proceeds from common stock issuance, partially offset by $0.7 million in repayments of short-term notes payable[404]. Debt and Interest - The company issued a $3.0 million promissory note in March 2025, which was repaid in full on July 2, 2025, using proceeds from the public offering[343]. - A $3.0 million promissory note was issued on March 13, 2025, with net proceeds of approximately $2.2 million after fees[405]. - The promissory note was non-interest bearing unless a default occurred, at which point interest would accrue at 20% per annum[406]. - Interest income rose to $182,229 in 2025, a significant increase of 297.04% from $45,897 in 2024[393]. - Interest expense surged to $785,930 in 2025 from $29,828 in 2024, an increase of 2,534.87% due to debt-related costs[393]. - Total short-term notes payable as of December 31, 2025, was $227,348, compared to $328,528 in 2024[410]. Operating Expenses - General and administrative expenses increased to $7 million in 2025 from $6.4 million in 2024, an increase of $525,464 or 8.1%[390]. - Total operating expenses were $9.4 million in 2025, down from $10.6 million in 2024, reflecting a decrease of $1.2 million or 11.3%[385]. - Cash used in operating activities was $9.2 million in 2025, compared to $8.6 million in 2024, reflecting higher working capital utilization[399]. Tax and Regulatory - The company has federal and state tax net operating loss carryforwards of $164.8 million and $138.5 million, respectively, as of December 31, 2025[368]. - The company does not have any off-balance sheet arrangements[412]. - As a smaller reporting company, the company is not required to provide information on market risk[413]. Inflation Impact - Inflation has not had a material impact on the company's operating results for the fiscal years ended December 31, 2025, and 2024[411].

Core Insights - Oragenics, Inc. has completed the first site initiation visit for its Phase IIa clinical trial of ONP-002 in Australia, marking the start of clinical trial operations at the first of three planned sites [2][3] - The remaining two sites are undergoing final administrative reviews before patient enrollment can begin, with expectations for completion in the near term [3][4] - The Phase IIa trial aims to evaluate the safety, tolerability, and preliminary clinical signals of ONP-002 in patients with acute concussion and mild traumatic brain injury [5][7] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on brain-targeted therapeutics using proprietary intranasal delivery technology [11] - The lead candidate, ONP-002, is a first-in-class intranasal neurosteroid in Phase IIa development for treating concussion and mild traumatic brain injury, conditions affecting approximately 69 million people globally each year without approved pharmacological treatments [11] Clinical Trial Details - The Phase IIa trial is a randomized, placebo-controlled study with an enrollment target of 40 patients across three sites in Australia [9] - The primary endpoints include safety assessments, neurocognitive follow-up evaluations, and participant compliance/tolerability [9] - The first dose is to be administered within 12 hours of concussion onset, with the first site now operational and ready to enroll patients [9][6]

Core Viewpoint - Oragenics, Inc. is actively exploring discussions for the potential acquisition of additional assets in the central nervous system (CNS) space, focusing on brain health and recovery, which align with its lead candidate ONP-002 and proprietary intranasal delivery technology [1][4]. Group 1: Company Strategy - The company is pursuing a portfolio expansion initiative independently of its existing partnership with Receptor.AI, which is focused on AI-enabled CNS drug discovery [2]. - Oragenics aims to build a diversified CNS portfolio through both traditional asset acquisition and AI-driven discovery strategies [2]. Group 2: ONP-002 Development - The Phase IIa clinical trial of ONP-002 is currently in active site initiation, with the first site visit completed in Australia and two additional sites undergoing final reviews [4][6]. - ONP-002 is the only pharmacological candidate in clinical development targeting the underlying biology of concussion and mild traumatic brain injury (mTBI), demonstrating safety and tolerability in a Phase 1 trial with 40 patients and zero serious adverse events [5]. - The company plans to submit an IND application to the FDA for continued clinical trials in the U.S. in 2027 following the Phase IIa trial [6]. Group 3: Intranasal Delivery Platform - Oragenics' proprietary intranasal drug delivery system allows for rapid, non-invasive delivery of therapeutic compounds directly to the brain, bypassing the blood-brain barrier [8][9]. - The company believes this platform can address significant challenges in CNS drug development, enhancing the efficiency and tolerability of delivering therapeutics to the brain [9]. Group 4: Strategic Fit for Acquisitions - The company is evaluating acquisition candidates based on criteria such as targeting neurological conditions, compatibility with intranasal delivery, and having meaningful preclinical or early clinical evidence [8]. - The strategic fit for potential acquisitions includes opportunities that complement the ongoing development of ONP-002 without displacing its advancement [8].

Core Insights - Oragenics, Inc. has received all necessary regulatory approvals to begin its Phase IIa clinical trial for ONP-002, a potential treatment for mild traumatic brain injury (mTBI) [1][2][5] - ONP-002 could become the first pharmacological treatment for concussion, addressing a significant unmet medical need in a market projected to exceed $9 billion by 2030 [2][5] - The drug is designed to target the underlying biology of mTBI, potentially shifting the treatment paradigm from symptom management to active intervention [2][8] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [9] - The company aims to address significant unmet medical needs in neurological care, with ONP-002 being its lead candidate for mTBI [9] Clinical Trial Details - The Phase IIa trial will involve 40 patients and is randomized and placebo-controlled, with dosing expected to occur within 12 hours of injury [4][5] - The trial will assess safety and tolerability through follow-up visits, including nasal examinations and neurocognitive testing [4] - The data readout from the Phase IIa trial is anticipated before the end of 2026, which will support a future investigational new drug (IND) application to the FDA [5][6] Market Potential - The global concussion market is projected to reach over $9 billion by 2030, highlighting the significant opportunity for ONP-002 if approved [2] - The nasal drug delivery market is also expected to grow, reaching nearly $93 billion by 2030, indicating a favorable environment for Oragenics' intranasal delivery platform [2][8] Safety and Efficacy - The Phase 1 clinical trial of ONP-002 demonstrated a strong safety profile, with zero serious adverse events reported across all dose levels [6] - Preclinical data indicated reductions in brain swelling, inflammation, and oxidative stress, along with improvements in functional recovery [6][8] Research and Development - Southern Star Research, a leading Australian clinical research organization, will manage the Phase IIa trial [7] - The company has spent years preparing for this trial, emphasizing a responsible and rigorous approach to development [2][3]

Core Insights - Oragenics, Inc. is advancing ONP-002, a novel intranasal neurosteroid, as a potential first pharmacological treatment for concussion and mild traumatic brain injury (mTBI) [1][3][11] - The company is well-prepared to initiate clinical site onboarding and first patient dosing in Australia for a Phase 2 clinical trial [1][2][8] Clinical Development - The Phase 2a clinical trial will evaluate 40 patients who meet specific enrollment criteria, with dosing occurring within 12 hours of concussion [10] - The trial aims to assess safety and tolerability through follow-up visits, including nasal examinations and neurocognitive testing [10] - Interim data from the Phase 2a trial is expected throughout 2026, with a final readout anticipated in Q4 2026 [8] Market Opportunity - The global concussion market is projected to exceed $9 billion by 2030, with ONP-002 positioned to be the first commercial treatment in this space [3][5] - The nasal drug delivery market is expected to reach nearly $93 billion by 2030, indicating significant potential for ONP-002 if approved [5] Financial Position - Oragenics raised $16.5 million through a public offering of Series H convertible preferred stock and warrants, supporting ongoing clinical development [8] - The company maintains a clean balance sheet with zero debt, fully funding the Phase 2a trial [8] Strategic Collaborations - A strategic collaboration has been formed with Receptor.AI to enhance drug discovery capabilities, potentially expanding the company's molecule portfolio beyond ONP-002 [8]

Core Insights - Oragenics, Inc. has engaged DUCK FLATS Pharma to support its U.S. Investigational New Drug (IND) readiness and regulatory execution for its novel intranasal concussion therapy, ONP-002, as it prepares for clinical trials in the U.S. [1][2] - The collaboration aims to ensure regulatory diligence and trial integrity, aligning the upcoming Phase 2a clinical trial in Australia with U.S. regulatory strategies [1][2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [5] - The lead candidate, ONP-002, is being advanced as a potential first-in-class treatment for concussion and mild traumatic brain injury, with ongoing Phase 2a trials in Australia and plans for U.S. Phase 2b trials [5] Market Potential - The global concussion market is projected to exceed $9 billion by 2027, indicating significant growth potential for innovative therapies in this area [4] - The nasal drug delivery market is expected to reach over $125 billion by 2030, highlighting the broader market opportunity for intranasal therapeutics [4] Collaboration Details - DUCK FLATS Pharma has a strong track record, having contributed to the development and approval of approximately 40 drug programs, including notable intranasal therapies [2][3] - The firm has extensive experience in regulatory and drug development, having managed over 400 regulatory documents and served as project lead on more than 60 FDA-approved New Drug Applications [2]

Core Insights - Oragenics, Inc. is preparing for its Phase 2a clinical trial of ONP-002, a concussion treatment, and is participating in the SCOPE Summit 2026 to engage with global clinical research leaders [1][2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [4] - The lead candidate, ONP-002, aims to address significant unmet medical needs in concussion and mild traumatic brain injury, with clinical trials planned in Australia and subsequent trials in the U.S. [4] Industry Engagement - The SCOPE Summit 2026 will host over 1,200 companies from 30 countries, covering topics such as trial planning, operations, and innovation in clinical research [3] - The event is seen as a critical opportunity for Oragenics to connect with experts in biopharma, scientific research, and regulatory affairs [2]

Core Insights - Oragenics, Inc. will present at the Sequire Investor Summit 2026, scheduled for January 20th-22nd, 2026, in San Juan, Puerto Rico [1] - The company aims to address the unmet medical need in concussion and mild traumatic brain injury with its lead candidate, ONP-002, which is advancing to Phase 2a clinical studies [2][3] Company Overview - Oragenics, Inc. is a clinical-stage biotechnology company focused on developing brain-targeted therapeutics using proprietary intranasal delivery technology [3] - The lead candidate, ONP-002, is being developed as a potential first-in-class treatment for concussion and mild traumatic brain injury, with ongoing Phase 2a trials in Australia and planned Phase IIb trials in the U.S. [3] - The intranasal delivery platform has potential applications for various neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders [3] Industry Context - Puerto Rico is an attractive location for investors due to its favorable tax benefits, making it home to many family offices and wealthy investors [2]